Catherine Hollingsworth

Aastrom heart stem cell trial on hold after adverse event

Feb. 4, 2009

By Catherine Hollingsworth

Aastrom Heart Stem Cell Trial on Hold After Adverse Event

Feb. 3, 2009

By Catherine Hollingsworth

Pro-Pharma Sees Clear Path to NDA for Davanat in Cancer

Jan. 30, 2009

By Catherine Hollingsworth

Exact to Get $24.5M in Deal with Genzyme

Jan. 29, 2009

By Catherine Hollingsworth

After rejecting a hostile bid by Sequenom Inc., Exact Sciences Corp. has entered a $24.5 million deal with Genzyme Corp. in a move that could help grow Exact's cancer diagnostics business. (BioWorld Today)

Theravance Files Telavancin NDA for Hospital-Acquired Pneumonia

Jan. 28, 2009

By Catherine Hollingsworth

Akesis Latest U.S. Biotech Firm to Face Bankruptcy

Jan. 23, 2009

By Catherine Hollingsworth

Tragara Pays $112M to Jointly Develop S*BIO Compound

Jan. 22, 2009

By Catherine Hollingsworth

Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million. (BioWorld Today)

Peptimmune, Novartis Sign $500M Deal for MS Drug

Jan. 20, 2009

By Catherine Hollingsworth

Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today)